Ariad’s Strategic Review, Step Two
Research - Ariad Pharmaceuticals (ARIA) took the second step in its ongoing strategic restructuring on Monday, announcing the sale of its European unit and rights to Iclusig … Continue Reading
Read NowzPremium
Simply Sit on That Sarepta Trade, and More Updates
Research - The NASDAQ Biotech Index Fund (IBB) failed to break out from $285 last week (discussed two weeks ago in our webinar) and subsequently lost key … Continue Reading
Premium: Read Now
Does The Latest For Linzess Read Through to Synergy?
Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
Premium: Read Now
Our First ‘Healthcare Huddle’ Webinar
Research - At PropThink, we experimented with some educational/informational webinars late in 2015 and early in 2016. The reception from our members was great.
Read Now
GW Pharma Spotlights Epilepsy; Other Opportunities Abound
Research - The 100% move from GW Pharmaceuticals (GWPH) on Monday is a good opportunity to circle back on another mid-cap epilepsy player that’s down 40% year-to-date and 60% from its highs last year.
Premium: Read Now
Nothing New From This Earnings Update
Research - Chimerix (CMRX) said in a conference call this morning that they now expect results from AdVise, which we wrote about last week, this spring.
Premium: Read Now
A Quiet Year for Bluebird Bio
Research - Bluebird bio (BLUE) reported quarterly earnings after the bell. As we’ve said before, this will be a quiet year for the company.
Read Now